UCK2

Summary

UCK2 (uridine-cytidine kinase 2, HGNC:12562) is a protein-coding gene on chromosome 1q24.1, encoding Uridine-cytidine kinase 2 (Q9BZX2). Phosphorylates uridine and cytidine to uridine monophosphate and cytidine monophosphate.

This gene encodes a pyrimidine ribonucleoside kinase. The encoded protein (EC 2.7.1.48) catalyzes phosphorylation of uridine and cytidine to uridine monophosphate (UMP) and cytidine monophosphate (CMP), respectively.

Source: NCBI Gene 7371 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 30 total
• Druggable target: yes
• MANE Select transcript: NM_012474

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12562
Approved symbol	UCK2
Name	uridine-cytidine kinase 2
Location	1q24.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000143179
Ensembl biotype	protein_coding
OMIM	609329
Entrez	7371

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 4 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000367879, ENST00000462329, ENST00000463772, ENST00000464197, ENST00000469256, ENST00000470820, ENST00000475333, ENST00000479872, ENST00000642653, ENST00000940421

RefSeq mRNA: 2 — MANE Select: NM_012474 NM_001363568, NM_012474

CCDS: CCDS1252, CCDS86027

Canonical transcript exons

ENST00000367879 — 7 exons

Exon	Start	End
ENSE00000958515	165891226	165891322
ENSE00001445845	165827614	165827932
ENSE00001656332	165890204	165890363
ENSE00003474372	165907684	165911618
ENSE00003674537	165896190	165896332
ENSE00003708517	165903182	165903279
ENSE00003711094	165905921	165905969

Expression profiles

Bgee: expression breadth ubiquitous, 238 present calls, max score 93.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 43.9980 / max 503.0526, expressed in 1815 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6398	25.5309	1797
6397	7.1215	1617
6400	5.4530	1622
6399	3.4218	1460
6405	1.1060	358
6406	0.5415	47
6402	0.2630	62
6407	0.2585	86
6403	0.1694	60
6404	0.1324	51

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	93.66	gold quality
ventricular zone	UBERON:0003053	91.47	gold quality
ganglionic eminence	UBERON:0004023	90.94	gold quality
embryo	UBERON:0000922	90.14	gold quality
stromal cell of endometrium	CL:0002255	89.73	gold quality
cortical plate	UBERON:0005343	89.69	gold quality
placenta	UBERON:0001987	89.14	gold quality
rectum	UBERON:0001052	88.58	gold quality
esophagus mucosa	UBERON:0002469	88.51	gold quality
lower esophagus mucosa	UBERON:0035834	87.95	gold quality
cartilage tissue	UBERON:0002418	87.44	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.83	gold quality
minor salivary gland	UBERON:0001830	86.70	gold quality
transverse colon	UBERON:0001157	86.29	gold quality
skin of abdomen	UBERON:0001416	86.12	gold quality
body of pancreas	UBERON:0001150	85.98	gold quality
mouth mucosa	UBERON:0003729	85.89	gold quality
skin of leg	UBERON:0001511	85.55	gold quality
islet of Langerhans	UBERON:0000006	85.51	gold quality
body of stomach	UBERON:0001161	85.47	gold quality
small intestine Peyer’s patch	UBERON:0003454	85.37	gold quality
secondary oocyte	CL:0000655	85.25	gold quality
esophagus	UBERON:0001043	85.24	gold quality
gastrocnemius	UBERON:0001388	85.19	gold quality
oocyte	CL:0000023	85.16	gold quality
gingival epithelium	UBERON:0001949	85.12	gold quality
ileal mucosa	UBERON:0000331	85.00	gold quality
gingiva	UBERON:0001828	84.72	gold quality
saliva-secreting gland	UBERON:0001044	84.60	gold quality
ascending aorta	UBERON:0001496	84.47	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.68
E-MTAB-6142	no	67.71

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1

miRNA regulators (miRDB)

127 targeting UCK2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-345-3P	99.89	70.23	1421

Literature-anchored findings (GeneRIF, showing 14)

• Increased intranuclear levels of UK may contribute to the metabolic build-up that is needed for Epstein-Barr virus nuclear protein EBNA-3-mediated B-cell blast transformation and rapid proliferation. (PMID:12199906)
• UCK2 is responsible for phosphorylation and activation of the antitumor activity of 3’-ethynyl nucleosides 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribopentofuranosyl)uridine. (PMID:15280220)
• gene mapped to chromosome 1. (PMID:16484797)
• B4GALT3, DAP3, RGS16, TMEM183A and UCK2–were significantly overexpressed in dup(1q)-positive ALLs compared with high hyperdiploid ALLs without dup(1q). (PMID:17613536)
• The mechanism of phosphate transfer in UCK2 is shown to be concerted, and is accompanied by concerted proton transfer from the 5’-hydroxyl to a conserved active site aspartic acid that serves as a catalytic base (PMID:19532987)
• Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. (PMID:23462292)
• Knockdown of endogenous UCK2 as well as overexpression of UCK1 resulted in decreased metabolism of uridine and cytidine and protected neuroblastoma cells from 3-deazauridine-induced toxicity. Subcellular localization studies showed that UCK1-GFP and UCK2-GFP were localized in the cell nucleus and cytosol, respectively. (PMID:27239701)
• accumulation of RX-3117 nucleotides correlated with UCK2 expression. (PMID:27612203)
• UCK1 and 2 are both expressed in several neuroblastoma cell lines, including four MYCN single copy cell lines and five MYCN amplified cell lines (PMID:27906629)
• survival analysis showed that only high methylation of cg0927774 was associated with better OS and RFS of HCC patients. Based on the findings above, we infer that UCK2 upregulation might be a valuable prognostic marker in hepatocellular carcinoma. The methylation of status cg0927774 might play a critical role in its expression (PMID:30304569)
• High UCK2 expression is associated with hepatocellular carcinoma aggressiveness. (PMID:30556610)
• Lung cancer patients with high UCK2 expression had poorer first progression survival and overall survival than patients with low UCK2 expression. Cytology experiments show that knockdown of UCK2 could suppress the proliferation and migration of lung cancer cells. Study indicated that UCK2 might be a potential early diagnostic and prognostic biomarker for lung cancer. (PMID:31278886)
• Targeting uridine-cytidine kinase 2 induced cell cycle arrest through dual mechanism and could improve the immune response of hepatocellular carcinoma. (PMID:36447138)
• Cytotoxic Flavokawain B Inhibits the Growth and Metastasis of Hepatocellular Carcinoma through UCK2 Modulation of the STAT3/Hif-1alpha/VEGF Signalling Pathway. (PMID:37534791)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	uck2a	ENSDARG00000006074
danio_rerio	uck2b	ENSDARG00000022213
mus_musculus	Uck2	ENSMUSG00000026558
rattus_norvegicus	Uck2	ENSRNOG00000003917
drosophila_melanogaster	Uck	FBGN0263398
caenorhabditis_elegans		WBGENE00007089

Paralogs (3): UPRT (ENSG00000094841), UCK1 (ENSG00000130717), UCKL1 (ENSG00000198276)

Protein

Protein identifiers

Uridine-cytidine kinase 2 — Q9BZX2 (reviewed: Q9BZX2)

Alternative names: Cytidine monophosphokinase 2, Testis-specific protein TSA903, Uridine monophosphokinase 2

All UniProt accessions (2): Q9BZX2, A0A2R8Y653

UniProt curated annotations — full annotation on UniProt →

Function. Phosphorylates uridine and cytidine to uridine monophosphate and cytidine monophosphate. Does not phosphorylate deoxyribonucleosides or purine ribonucleosides. Can use ATP or GTP as a phosphate donor. Can also phosphorylate cytidine and uridine nucleoside analogs such as 6-azauridine, 5-fluorouridine, 4-thiouridine, 5-bromouridine, N(4)-acetylcytidine, N(4)-benzoylcytidine, 5-fluorocytidine, 2-thiocytidine, 5-methylcytidine, and N(4)-anisoylcytidine.

Subunit / interactions. Homotetramer.

Tissue specificity. According to PubMed:8812458; testis-specific. According to PubMed:11306702, placenta-specific.

Pathway. Pyrimidine metabolism; CTP biosynthesis via salvage pathway; CTP from cytidine: step 1/3. Pyrimidine metabolism; UMP biosynthesis via salvage pathway; UMP from uridine: step 1/1.

Similarity. Belongs to the uridine kinase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BZX2-1	1	yes
Q9BZX2-2	2

RefSeq proteins (2): NP_001350497, NP_036606* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000764	Uridine_kinase-like	Family
IPR006083	PRK/URK	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00485

Enzyme classification (BRENDA):

• EC 2.7.1.48 — uridine/cytidine kinase (BRENDA: 11 organisms, 140 substrates, 53 inhibitors, 88 Km, 32 kcat entries)

Substrate kinetics (BRENDA)

7 substrates with measured Km, best-characterized 7. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
CYTIDINE	0.023–4	38
URIDINE	0.04–11.5	31
ATP	0.062–5	10
5-FLUOROURIDINE	0.03–0.069	2
3-DEAZAURIDINE	0.2	1
5-AZACYTIDINE	11	1
6-AZAURIDINE	0.34	1

Catalyzed reactions (Rhea), 2 shown:

• uridine + ATP = UMP + ADP + H(+) (RHEA:16825)
• cytidine + ATP = CMP + ADP + H(+) (RHEA:24674)

UniProt features (41 total): helix 14, binding site 8, strand 7, modified residue 2, sequence conflict 2, region of interest 2, turn 2, initiator methionine 1, chain 1, splice variant 1, compositionally biased region 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
1UJ2	X-RAY DIFFRACTION	1.8
1XRJ	X-RAY DIFFRACTION	2
7SQL	X-RAY DIFFRACTION	2.4
6N54	X-RAY DIFFRACTION	2.42
1UFQ	X-RAY DIFFRACTION	2.5
1UDW	X-RAY DIFFRACTION	2.6
1UEI	X-RAY DIFFRACTION	2.6
1UEJ	X-RAY DIFFRACTION	2.61
6N53	X-RAY DIFFRACTION	2.7
6PWZ	X-RAY DIFFRACTION	3
6N55	X-RAY DIFFRACTION	3.08

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BZX2-F1	86.52	0.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 176; 184; 213; 27–35; 84; 112; 117; 166

Post-translational modifications (2): 2, 254

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-73614	Pyrimidine salvage

MSigDB gene sets: 346 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, MODULE_52, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, TSENG_IRS1_TARGETS_UP, GOBP_BEHAVIOR, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, BASSO_B_LYMPHOCYTE_NETWORK, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE, GOBP_PYRIMIDINE_NUCLEOSIDE_TRIPHOSPHATE_BIOSYNTHETIC_PROCESS, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP

GO Biological Process (6): feeding behavior (GO:0007631), UMP salvage (GO:0044206), CTP salvage (GO:0044211), response to axon injury (GO:0048678), cellular response to oxygen levels (GO:0071453), CMP biosynthetic process (GO:0009224)

GO Molecular Function (7): uridine kinase activity (GO:0004849), ATP binding (GO:0005524), identical protein binding (GO:0042802), cytidine kinase activity (GO:0043771), nucleotide binding (GO:0000166), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Nucleotide salvage	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
UMP biosynthetic process	2
pyrimidine ribonucleotide salvage	2
nucleoside kinase activity	2
cellular anatomical structure	2
behavior	1
CTP biosynthetic process	1
response to wounding	1
response to oxygen levels	1
cellular response to chemical stimulus	1
pyrimidine ribonucleoside monophosphate biosynthetic process	1
pyrimidine ribonucleotide biosynthetic process	1
CMP metabolic process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
protein binding	1
CMP biosynthetic process	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

2231 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UCK2	PASK	Q96RG2	891
UCK2	CMPK1	P30085	799
UCK2	UMPS	P11172	768
UCK2	PPP1R7	Q15435	764
UCK2	UPP2	O95045	763
UCK2	UPP1	Q16831	754
UCK2	TYMS	P04818	739
UCK2	TK1	P04183	692
UCK2	UPRT	Q96BW1	683
UCK2	GYS1	P13807	662
UCK2	DCK	P27707	608
UCK2	DTYMK	P23919	584
UCK2	RNF19B	Q6ZMZ0	577
UCK2	CDA	P32320	575
UCK2	TYMP	P19971	563

IntAct

59 interactions, top by confidence:

A	B	Type	Score
MED20	MED19	psi-mi:“MI:0914”(association)	0.840
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
UCK2	UCK2	psi-mi:“MI:0915”(physical association)	0.560
UPRT	SERPINB4	psi-mi:“MI:0914”(association)	0.530
UCK2	IAH1	psi-mi:“MI:0914”(association)	0.530
TNFSF8	LGALS8	psi-mi:“MI:0914”(association)	0.530
UPRT	UCK2	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
KSR1	FBLL1	psi-mi:“MI:0914”(association)	0.350
DLD	NFKBIE	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
	AGPS	psi-mi:“MI:0914”(association)	0.350
TLK2	IGKV1D-13	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
GPR45	VWA8	psi-mi:“MI:0914”(association)	0.350
OPALIN	FAM171A2	psi-mi:“MI:0914”(association)	0.350
MFSD4A	UBXN8	psi-mi:“MI:0914”(association)	0.350
PROKR1	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
F2RL1	TNPO2	psi-mi:“MI:0914”(association)	0.350
CACNG7	PLD2	psi-mi:“MI:0914”(association)	0.350
CACNG4	TTI1	psi-mi:“MI:0914”(association)	0.350
WDTC1	PHGDH	psi-mi:“MI:0914”(association)	0.350
UCK2	DCAF6	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
ARMC6	DDX39A	psi-mi:“MI:0914”(association)	0.350

BioGRID (82): UCK2 (Affinity Capture-MS), UCK2 (Affinity Capture-MS), UCK2 (Affinity Capture-MS), UCK1 (Affinity Capture-MS), UCKL1 (Affinity Capture-MS), IAH1 (Affinity Capture-MS), VARS2 (Affinity Capture-MS), UCK2 (Affinity Capture-MS), UCK2 (Affinity Capture-MS), UCK2 (Affinity Capture-RNA), UCK2 (Affinity Capture-MS), UCK2 (Affinity Capture-MS), UCK2 (Affinity Capture-MS), AKT1 (Affinity Capture-Western), UCK2 (Positive Genetic)

ESM2 similar proteins: A4IFD0, A4IG62, A7GT59, B1H116, B5FG51, C0ZAS6, O00763, O23617, P16118, P32232, P49872, P52623, P70266, Q0P5A4, Q13057, Q4R4K2, Q5E3Z9, Q5EBA1, Q5R9C1, Q5T6J7, Q5VV42, Q66I71, Q6AY55, Q6GPD9, Q6P4Y0, Q6PA79, Q7L5N7, Q7SYM0, Q7ZV79, Q80YD1, Q8IYB8, Q8MIR4, Q8T154, Q8WV93, Q91309, Q91348, Q91WE6, Q91YL3, Q920P5, Q99PM9

Diamond homologs: A0Q140, A2RDZ9, A2RJB4, A4IR72, A5ITD6, A5VKU8, A6QHF2, A6TR08, A6U280, A7GGE1, A7GT59, A7X320, A7Z727, A8AWT2, A8FFL8, A8YU29, A8Z4E9, A9WCC8, B1H116, B1IJ68, B1KXA7, B1MXP1, B2G882, B4U220, B5XM21, B7GIU0, B8G8N0, B9DNJ4, B9DSN2, B9E6Y9, B9LED5, C0M9M0, C0MCM8, C0ZAS6, C1FSX6, C3L140, C5D4Y5, O32033, O65583, O74427

SIGNOR signaling

9 interactions.

A	Effect	B	Mechanism
UCK2	“down-regulates quantity”	ATP(4-)	“chemical modification”
UCK2	“up-regulates quantity”	ADP(3-)	“chemical modification”
UCK2	“down-regulates quantity”	cytidine	“chemical modification”
UCK2	“up-regulates quantity”	“cytidine 5’-monophosphate(2-)”	“chemical modification”
UCK2	“down-regulates quantity”	uridine	“chemical modification”
UCK2	“up-regulates quantity”	“uridine 5’-monophosphate(2-)”	“chemical modification”
METTL3	“up-regulates quantity by stabilization”	UCK2	“post transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1651 predictions. Top by Δscore:

Variant	Effect	Δscore
1:165890201:C:G	acceptor_gain	1.0000
1:165890202:A:AG	acceptor_gain	1.0000
1:165890203:G:GG	acceptor_gain	1.0000
1:165890203:GTCTT:G	acceptor_gain	1.0000
1:165890362:GG:G	donor_gain	1.0000
1:165890363:GG:G	donor_gain	1.0000
1:165891220:TTTCA:T	acceptor_loss	1.0000
1:165891221:TTCA:T	acceptor_loss	1.0000
1:165891222:TCA:T	acceptor_loss	1.0000
1:165891223:CAGAT:C	acceptor_loss	1.0000
1:165891224:A:AG	acceptor_gain	1.0000
1:165891224:AG:A	acceptor_loss	1.0000
1:165891225:G:GC	acceptor_gain	1.0000
1:165891225:GAT:G	acceptor_gain	1.0000
1:165903276:GCCA:G	donor_gain	1.0000
1:165903280:G:GG	donor_gain	1.0000
1:165905915:CCACA:C	acceptor_loss	1.0000
1:165905916:CACA:C	acceptor_loss	1.0000
1:165905917:ACAG:A	acceptor_loss	1.0000
1:165905918:CA:C	acceptor_loss	1.0000
1:165905919:A:AG	acceptor_gain	1.0000
1:165905920:G:GC	acceptor_gain	1.0000
1:165905920:GAC:G	acceptor_gain	1.0000
1:165905968:GG:G	donor_gain	1.0000
1:165905969:GG:G	donor_gain	1.0000
1:165907682:A:AG	acceptor_gain	1.0000
1:165907682:AGT:A	acceptor_gain	1.0000
1:165907683:G:GG	acceptor_gain	1.0000
1:165907683:GT:G	acceptor_gain	1.0000
1:165907683:GTG:G	acceptor_gain	1.0000

AlphaMissense

1721 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:165896239:G:A	G136R	1.000
1:165896239:G:C	G136R	1.000
1:165896293:T:C	F154L	1.000
1:165896295:T:A	F154L	1.000
1:165896295:T:G	F154L	1.000
1:165896311:G:C	D160H	1.000
1:165896321:T:C	L163P	1.000
1:165903268:T:C	F196L	1.000
1:165903270:C:A	F196L	1.000
1:165903270:C:G	F196L	1.000
1:165905934:C:A	A204D	1.000
1:165907696:T:C	L220P	1.000
1:165827904:G:A	G24D	0.999
1:165827912:G:A	G27R	0.999
1:165827912:G:C	G27R	0.999
1:165827912:G:T	G27W	0.999
1:165827913:G:A	G27E	0.999
1:165827915:G:A	G28R	0.999
1:165827915:G:C	G28R	0.999
1:165827924:A:C	S31R	0.999
1:165827926:C:A	S31R	0.999
1:165827926:C:G	S31R	0.999
1:165827927:G:C	G32R	0.999
1:165827928:G:A	G32D	0.999
1:165827928:G:T	G32V	0.999
1:165890294:T:C	F64L	0.999
1:165890296:C:A	F64L	0.999
1:165890296:C:G	F64L	0.999
1:165890350:C:A	N82K	0.999
1:165890350:C:G	N82K	0.999

dbSNP variants (sampled 300 via entrez): RS1000000607 (1:165851595 G>C), RS1000026347 (1:165831236 G>A), RS1000066710 (1:165859978 G>A), RS1000136715 (1:165892884 G>A), RS1000166298 (1:165855523 T>C), RS1000187128 (1:165911870 T>A), RS1000215890 (1:165855753 G>A), RS1000219144 (1:165894432 C>T), RS1000221538 (1:165849004 C>T), RS1000235743 (1:165886299 C>G), RS1000331180 (1:165839882 T>C), RS1000348389 (1:165857740 C>A), RS1000406161 (1:165839763 G>A), RS1000426324 (1:165842882 C>A,T), RS1000431840 (1:165843334 T>C)

Disease associations

OMIM: gene MIM:609329 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002022_12	Testicular germ cell tumor	2.000000e-08
GCST002023_7	Testicular germ cell tumor	6.000000e-06
GCST002855_4	Testicular germ cell tumor	2.000000e-07
GCST004635_3	Testicular germ cell tumor	5.000000e-11
GCST004713_14	Testicular germ cell tumor	2.000000e-14
GCST009597_237	Multiple sclerosis	8.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2469 (SINGLE PROTEIN), CHEMBL3542438 (PROTEIN FAMILY), CHEMBL4748231 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

6 potent at pChembl≥5 of 17 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.00	Ki	1000	nM	CHEMBL1592234
5.52	IC50	3000	nM	CHEMBL1592234
5.46	Ki	3500	nM	CHEMBL1592234
5.42	IC50	3800	nM	CHEMBL1592234
5.33	IC50	4700	nM	CHEMBL4588628
5.04	IC50	9200	nM	CHEMBL4553820

PubChem BioAssay actives

6 with measured affinity, of 65 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[[2-[[9-methyl-2-(4-methylphenyl)-5H-chromeno[2,3-d]pyrimidin-4-yl]sulfanyl]acetyl]amino]benzoic acid	1589138: Non-competitive inhibition of C-terminally His6-tagged human UCK2 expressed in Escherichia coli BL21(DE3) cells using uridine, phosphoenolpyruvate, NADH and varying ATP level by spectrophotometry based pyruvate kinase and lactate dehydrogenase coupled enzyme assay	ki	1.0000	uM
3-[[2-[(9-methyl-2-phenyl-5H-chromeno[2,3-d]pyrimidin-4-yl)sulfanyl]acetyl]amino]benzoic acid	1589134: Inhibition of C-terminally His6-tagged human UCK2 expressed in Escherichia coli BL21(DE3) cells incubated for 15 mins before ATP addition and measured after 60 mins by ADP-Glo kinase assay	ic50	4.7000	uM
N-(4-bromophenyl)-2-[[1-(4-fluorophenyl)-4-oxo-5H-pyrazolo[5,4-d]pyrimidin-6-yl]sulfanyl]acetamide	1589135: Inhibition of C-terminally His6-tagged human UCK2 expressed in Escherichia coli BL21(DE3) cells incubated for 15 mins before ATP addition and measured after 60 mins by ADP-Glo kinase assay based HTS assay	ic50	9.2000	uM

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression, affects cotreatment	4
Estradiol	increases expression	3
sodium arsenite	decreases expression, increases expression	2
Fluorouracil	decreases expression, affects response to substance	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
GSK-J4	decreases expression	1
afuresertib	decreases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
methylselenic acid	decreases expression	1
trichostatin A	affects expression	1
cobaltous chloride	decreases expression	1
benzo(e)pyrene	increases methylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
2’-C-methylcytidine	decreases phosphorylation, increases phosphorylation	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	increases methylation	1
Benzoates	decreases expression	1
Calcitriol	decreases expression, affects cotreatment	1
Carbamazepine	affects expression	1
Coumestrol	affects cotreatment, increases expression	1

ChEMBL screening assays

25 unique, capped per target: 25 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4387679	Binding	Inhibition of C-terminally His6-tagged human UCK2 expressed in Escherichia coli BL21(DE3) cells incubated for 15 mins before ATP addition and measured after 60 mins by ADP-Glo kinase assay	Discovery of small molecule inhibitors of human uridine-cytidine kinase 2 by high-throughput screening. — Bioorg Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XU88	HAP1 UCK2 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.